Trial intelligence / Profile preview

MTA vs Biodentine in Pulpotomy for Traumatized Immature Teeth

NCT03838068Phase 3Completed

Start: Jan 2017
Primary completion: Dec 2018
Countries: 1

Overview

Phase 3, randomised, single-blind trial of Biodentine in reversible pulpitis. Primary endpoints: Presence of pain, sensitivity to percussion/palpation at 18 months and Presence of swelling or sinus tract at 18 months. Started Jan 2017; status: completed.

Drugs

Biodentine

Conditions

reversible pulpitis

Beyond the preview

Go deeper on NCT03838068.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03838068.